Lyra Therapeutics Investor Relations Material

Lyra Therapeutics Inc. is a clinical-stage biotechnology firm dedicated to developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS). CRS is an inflammatory disease of the paranasal sinuses that results in prolonged periods of nasal congestion, facial pain, and nasal discharge. Leveraging expertise in materials science, drug development, and formulation, Lyra has introduced proprietary technology aimed at delivering medications directly, precisely, and consistently to the affected tissue for extended durations with a single administration. The company's leading product candidates include LYR-210 and LYR-220, both bioresorbable nasal implants designed for in-office procedures, intended to provide up to six months of continuous drug therapy to the sinonasal passages for CRS treatment. The company is headquartered in Watertown, Massachusetts, and its shares are listed on the Nasdaq.